Drug Safety
This has been an interesting ACR meeting in terms of PMR updates. I would argue that we are still far too wedded to glucocorticoids only in the management of PMR. Yes, some patients will do fine with just glucocorticoids but we persist far too long with a glucocorticoid only strategy in others who clearly need an alternative as glucocorticoid adverse events multiply.
Richard Conway RichardPAConway
10 months 2 weeks ago
TNFis preventing cancer compared to placebo, and JAKi being neutral to placebo and maybe preventing haem cancers also. #ACR24 abstract 0989 was certainly provocative. I've shared my thoughts on @RheumNow https://t.co/yQFoUGifEN
Dr. John Cush RheumNow
10 months 2 weeks ago
Potential Impact of Weight Loss Drugs in Rheumatic Diseases
Dr. Arthur Kavanaugh highlights a session regarding weight loss and improvement in disease outcomes, specific weight loss drugs (SGL-2 and GLP-1), along with downsides when patients stop these medications. Reporting… https://t.co/Ilu2FXK2xi https://t.co/7CKSnfuey4
Eric Dein ericdeinmd
10 months 2 weeks ago
A#2651
Vasculitis w VEXAS
81 men, median age 67 - 27% had evid of vasculitis, variable size vessel
22% SVV- 17/18 cutaneous, one peritubular capillaritis on renal bx
2.5% MVV (2 cutan), LVV (2 carotid thickening, 1 had +TA bx), ANCA+
@RheumNow #ACR24 https://t.co/puablIBLCP
Mrinalini Dey DrMiniDey
10 months 2 weeks ago
What factors are assoc with uptake of newer meds in RA?
➡️Incr use of b/tsDMARDs over 10yrs
➡️Use of newer drugs lower in older ppl, socioeconomic deprived & Asian/Black ppl
Could this indicate disparities in access to meds? How can we best address this?
Ab2608 #ACR24 @RheumNow
Eric Dein ericdeinmd
10 months 2 weeks ago
A#2652
NEWTON study 🇫🇷 Retrosp cohort
51% relapse. Median @8.7 mos, dose 9mg pred
Rf: limb art involv- HR 1.9
Pred taper speed not risk for relapse
Most relapse -> incr GCs
Toci 1/3 at dx, 50% stopped
-61% d/c due to remission, 39% SEs
-1/3 relapse after d/c
@RheumNow #ACR24 https://t.co/NP0wieDmvo
Richard Conway RichardPAConway
10 months 2 weeks ago
Peyrac et al. 211 GCA. Relapse in 52% at median 261 days (so 1st year). 83% on GCs at relapse, median dose 6.5mg pred. 36% relapse post-toc discontinuation, at median 133 days. 64% no relapse when toc stopped, at median 511 days @RheumNow #ACR24 Abstr#2652 https://t.co/NqtdDNGGoc https://t.co/mXD8x7O6Ww
Eric Dein ericdeinmd
10 months 2 weeks ago
A#2648
PET for GCA
Delayed imaging at 180 min improve dx performance for pts on GCs
Optimal PET w/in 3 days of GC, most patients unable to do w/in that window
Delay has sensitivity 92% even on prednisone - may be good tool for pts unable to get early PET/CT
#ACR24 @RheumNow https://t.co/kxpNfRqkGN
Antoni Chan MD (Prof) synovialjoints
10 months 2 weeks ago
Study by Maria Dall'Era et al. compared voclosporin-based triple immunosuppressive therapy with high-dose GC in active lupus nephritis.
- Fewer adverse events in the voclosporin group, despite a higher incidence of specific issues like decreased GFR and hypertension.
- 25%… https://t.co/ToRu2rdErC https://t.co/uUXzNNuLDb
Mrinalini Dey DrMiniDey
10 months 2 weeks ago
How do you manage DMARDs when giving the recombinant #zoster #vaccine (#RZV)?
➡️75 pts with ARDs
💉2-week #MTX discontinuation after each dose of RZV
⏩Significant boost in immune response without difference in flare rates
Ab2612 #ACR24 @RheumNow https://t.co/o4iqj3e1Be
sheila RHEUMarampa
10 months 2 weeks ago
Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO
Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO
@RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4
Eric Dein ericdeinmd
10 months 2 weeks ago
A#2582 McInnes
Sonelokimab - IL17A,F nanobody
Prior P2 in PsO, HS
ARGO: P2 W24 RCT
Significant improv in ACR response
High PASI90/100 data
Up to 60% achieved MDA by W24
Improved PsAID domains (PRO)
Safety no IBD, MACE, depr. 2% oral candida
IZAR-1,2 - P3 ongoing
#ACR24 @RheumNow https://t.co/O4fEhTC8jK
sheila RHEUMarampa
10 months 2 weeks ago
SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study.
Reasons for stopping SEC:
lack of efficacy
pt decision
lost to ffup
AEs
Reassuring data on SECs position in the treatment of PsA/AS.
@Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi
Poster Hall